AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the launch of Tylactin™ RESTORE Powder, a medical food hydration beverage, available in convenient portable single-serve stick-packs for the dietary management of Tyrosinemia (TYR).
Tylactin with GMP is made from a natural whole protein derived from whey called glycomacropeptide (GMP). Cambrooke Therapeutics was the first company to provide individuals with Tyrosinemia natural whole protein medical foods—Tylactin RTD and Tylactin RESTORE. Now, Tylactin RESTORE Powder provides an additional option for individuals struggling to consume their formula or those people who need a compact, easy-to-mix, and great-tasting formula.
Tylactin RESTORE Powder contains 5g protein equivalents (PE). The formulation is a great option for those with an active lifestyle as it helps to replenish electrolytes lost during activities. Tylactin RESTORE Powder comes in an all-natural, great-tasting orange flavor. The stick-pack shape of the Tylactin RESTORE Powder packets makes them easy to mix into a bottle of water or an on-the-go sports bottle. Tylactin RESTORE Powder is an ideal addition to any TYR diet program for use at school, during sports or any time on-the-go convenience is desired.
“The formula options are so limited for the Tyrosinemia community. I continually struggled to take my formula,” says Michael D., a teenager with TYR. “I never really liked my formula, but I had to take it because there was nothing else available. With the Tylactin products, I not only have a great tasting product, but it’s so convenient to take. I actually look forward to drinking my formula.”
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available atwww.cambrooke.com.